Feb 21 |
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
|
Jan 29 |
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
|
Jan 3 |
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
|
Dec 22 |
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Dec 21 |
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Dec 21 |
Longeveron stock plummets on $2.36M registered direct offering priced at $1.62/share
|
Dec 21 |
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Dec 20 |
Longeveron reports positive results from Alzheimer's treatment trial
|
Dec 20 |
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
|
Nov 15 |
Longeveron files to sell 5.02M shares of class A common stock for holders
|